Developer docs
API playgroundTry for free, no card

Search company profiles

Leyden Labs

Full company profile

uuid00004l3

Namestring
Leyden Labs
Legal namestring
Leyden Laboratories B.V.
Websiteurl
leydenlabs.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Leyden Laboratories B.V. is a Dutch clinical-stage biotechnology company founded in 2020 and headquartered in Amsterdam that develops intranasal antibody-based nasal sprays designed to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. Its lead asset, PanFlu, delivers the broadly neutralizing CR9114 antibody directly to the respiratory mucosa via nasal spray, and demonstrated safety, tolerability, and protective mucosal antibody concentrations in a Phase 1 study of 143 healthy volunteers, with non-human primate studies confirming protection against H1N1 challenge. These data were published in Science Translational Medicine and underpin the company's Mucosal Protection Platform, which positions the technology as a non-vaccine, mutation-resilient alternative to traditional flu vaccines that average roughly 13% effectiveness against infection.

The company has raised approximately $358 million+ cumulatively since inception, anchored by a $140-200 million 2021/2022 Series B led by Casdin Capital and GV (with SoftBank Vision Fund, F-Prime, Invus, Polaris Partners, Qiming Venture Partners and others), supplemented by 2025-2026 tranches from the European Investment Bank (€20M debt, HERA-facilitated), the European Innovation Council Fund and Invest-NL (€30M; €40M), and the Gates Foundation Strategic Investment Fund alongside ClavystBio. In January 2025 the company acquired CoV Biotechnology to extend its pandemic preparedness footprint into Asia. Investors have signaled a pre-money valuation of approximately $800M during the Series B, implying an estimated ~$1B post-money valuation.

Commercially, Leyden Labs is pre-revenue with no products approved. Its go-to-market strategy targets healthcare provider and government procurement channels for pandemic preparedness stockpiling, alongside a global public health / LMIC access pathway enabled by Gates Foundation participation. Distribution is anticipated through hospital and clinic channels, government health authority stockpiling, and international organizations, with supporting GTM motion described as enterprise field sales to public sector and global health buyers. The company is led by Co-Founder/CEO Koenraad Wiedhaup and CSO Clarissa Koch, with Founder Jaap Goudsmit and Founder/CBO Ronald Brus, Executive Chairman Dinko Valerio, and CMO Jintanat Ananworanich providing senior leadership; Ben Verwaayen joined the Supervisory Board in June 2026.

Short descriptiontext

Leyden Labs is a Dutch clinical-stage biotech founded in 2020 developing intranasal antibody nasal sprays, led by PanFlu, which deliver broadly neutralizing antibodies to the respiratory mucosa for immediate protection against influenza and other respiratory viruses, serving governments and global health buyers for pandemic preparedness.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intranasal antibody therapy, respiratory virus prophylaxis, pandemic preparedness solutions, broadly neutralizing antibodies, mucosal protection platform
Industry6 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
Product category
Infectious Disease Prophylactics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Leyden Labs is developing and advancing toward commercialization of its intranasal antibody nasal spray products (PanFlu) for influenza and other respiratory virus prevention. The company aims to bring these products to market as prophylactic treatments for healthcare providers, governments, and potentially consumers for pandemic preparedness.

businesswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PanFlu
Description

Intranasal spray candidate delivering broadly neutralizing CR9114 antibody for protection against influenza and other respiratory viruses at the point of viral entry.

globenewswire.com
+1 more record
Core offering1 text field

Leyden Labs develops intranasal antibody-based nasal sprays that deliver broadly neutralizing antibodies directly to the respiratory mucosa to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. The company's lead candidate, PanFlu, uses the CR9114 antibody and is advancing through clinical trials toward regulatory approval and commercialization for pandemic preparedness and public health use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 studies (n=143 healthy volunteers) demonstrated that intranasal delivery of CR9114 antibody was safe, well-tolerated, and achieved protective concentrations in nasal mucosa
+2 more records
Product overview1 text field

Leyden Labs is developing a portfolio of intranasal antibody-based products targeting respiratory viruses. The company's lead product is PanFlu, an antibody-based nasal spray using the broadly neutralizing CR9114 antibody. This is enabled by the company's Mucosal Protection Platform technology, which delivers protective antibodies directly to the nasal mucosa. The products aim to provide immediate, broad-spectrum protection against influenza, coronaviruses, and other respiratory viruses at the point of viral entry.

Product and service2 records
1PanFlu
CategoryIntranasal Antiviral Prophylactic
Description

An antibody-based intranasal nasal spray for influenza prevention that delivers the broadly neutralizing CR9114 antibody directly to the respiratory mucosa. Phase 1 clinical studies demonstrated safety, tolerability, and protective antibody concentrations in 143 healthy volunteers, with non-human primate studies confirming protection against H1N1 infection and reduced viral load. Targeted at healthcare providers, governments, and global public health programs for pandemic preparedness.

2Mucosal Protection Platform
CategoryBiotechnology Platform
Description

A technology platform that delivers broadly protective antibodies directly to the respiratory mucosa (nose and throat) to provide immediate protection against respiratory viruses including influenza and coronaviruses. Underpins Leyden Labs' intranasal product pipeline, including the lead candidate PanFlu.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Ben Verwaayen (Supervisory Board Member)
Strategic tierMinorTypeOthersAnnounced on2026-06-26
Description

Appointed to the Supervisory Board, bringing international leadership experience from senior executive roles at global technology companies. Nominated by EIC Fund and Invest-NL.

pulse2.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-09
Description

Acquired CoV Biotechnology to strengthen Leyden Labs' pandemic preparedness efforts in Asia. The acquisition expands the company's capabilities and geographic footprint in Asian markets for respiratory virus protection.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Facilitated the €20 million EIB investment to advance Leyden Labs' intranasal antibody approach for pandemic preparedness in Europe. Represents a strategic alignment with European public health preparedness priorities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Moderna is a leading mRNA vaccine and therapeutics company developing respiratory virus vaccines including mRNA-1010 and mRNA-1083 (flu+COVID combinations). It competes with Leyden Labs for the same pandemic preparedness and seasonal flu prophylaxis market, but with a fundamentally different technology platform (mRNA vs intranasal antibodies).

TypeBroad incumbent
Description

BioNTech is a leading mRNA therapeutics company with COVID and influenza vaccine programs and a broad oncology and infectious disease pipeline. It is comparable to Leyden Labs as a competing modality addressing the same pandemic preparedness and respiratory virus prophylaxis use cases.

TypeBroad incumbent
Description

Regeneron is a leading monoclonal antibody company whose REGN-COV2 (casirivimab/imdevimab) demonstrated the feasibility of antibody-based prophylaxis for respiratory viruses. As a large biotech with established mAb manufacturing, it represents both a potential competitor and likely strategic acquirer of intranasal antibody programs like Leyden's.

TypeDirect peer
Description

Vir Biotechnology is a clinical-stage immunology company developing antibody-based therapeutics for serious infectious diseases including influenza (sotrovimab, VIR-2482) and COVID-19. It is the closest direct peer to Leyden Labs, pursuing prophylactic monoclonal antibodies against respiratory viruses through a different delivery route (intramuscular vs intranasal).

TypeBroad incumbent
Description

AstraZeneca developed Evusheld (tixagevimab/cilgavimab), the leading antibody prophylaxis for COVID-19 in immunocompromised patients. It is comparable to Leyden Labs as a competing prophylactic mAb franchise targeting pandemic preparedness stockpiling budgets.

TypeDirect peer
Description

Arcturus is a clinical-stage mRNA and lipid nanoparticle company developing self-amplifying mRNA vaccines including a pandemic influenza vaccine (ARCT-2138). It is comparable to Leyden Labs as a competing modality addressing the same broad-protection influenza use case.

TypeDirect peer
Description

CureVac is a clinical-stage mRNA company developing vaccines for infectious diseases including seasonal and pandemic influenza (CVSQIV). It competes with Leyden Labs for the same broad-protection respiratory virus market with an alternative technology platform.

TypeDirect peer
Description

Invivyd is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for COVID-19 and other viral diseases, with a focus on durable monoclonal antibodies for prophylaxis. It is directly comparable to Leyden Labs as a competing mAb-focused pandemic preparedness company.

TypeBroad incumbent
Description

CSL Seqirus is one of the world's largest influenza vaccine manufacturers and a major pandemic preparedness partner to governments. It is comparable to Leyden Labs as the incumbent channel and likely competitor/distributor for intranasal antibody products in government stockpiling markets.

TypeEmerging player
Description

Hummingbird Bioscience is a clinical-stage biotechnology company developing precision-engineered antibody therapeutics for oncology and infectious diseases. It is comparable to Leyden Labs as a fellow emerging antibody platform company, though focused on different therapeutic areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leyden Labs

Infectious Disease Prophylacticsleydenlabs.com

Leyden Labs is a Dutch clinical-stage biotech founded in 2020 developing intranasal antibody nasal sprays, led by PanFlu, which deliver broadly neutralizing antibodies to the respiratory mucosa for immediate protection against influenza and other respiratory viruses, serving governments and global health buyers for pandemic preparedness.

What Leyden Labs does

Leyden Laboratories B.V. is a Dutch clinical-stage biotechnology company founded in 2020 and headquartered in Amsterdam that develops intranasal antibody-based nasal sprays designed to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. Its lead asset, PanFlu, delivers the broadly neutralizing CR9114 antibody directly to the respiratory mucosa via nasal spray, and demonstrated safety, tolerability, and protective mucosal antibody concentrations in a Phase 1 study of 143 healthy volunteers, with non-human primate studies confirming protection against H1N1 challenge. These data were published in Science Translational Medicine and underpin the company's Mucosal Protection Platform, which positions the technology as a non-vaccine, mutation-resilient alternative to traditional flu vaccines that average roughly 13% effectiveness against infection.

The company has raised approximately $358 million+ cumulatively since inception, anchored by a $140-200 million 2021/2022 Series B led by Casdin Capital and GV (with SoftBank Vision Fund, F-Prime, Invus, Polaris Partners, Qiming Venture Partners and others), supplemented by 2025-2026 tranches from the European Investment Bank (€20M debt, HERA-facilitated), the European Innovation Council Fund and Invest-NL (€30M; €40M), and the Gates Foundation Strategic Investment Fund alongside ClavystBio. In January 2025 the company acquired CoV Biotechnology to extend its pandemic preparedness footprint into Asia. Investors have signaled a pre-money valuation of approximately $800M during the Series B, implying an estimated ~$1B post-money valuation.

Commercially, Leyden Labs is pre-revenue with no products approved. Its go-to-market strategy targets healthcare provider and government procurement channels for pandemic preparedness stockpiling, alongside a global public health / LMIC access pathway enabled by Gates Foundation participation. Distribution is anticipated through hospital and clinic channels, government health authority stockpiling, and international organizations, with supporting GTM motion described as enterprise field sales to public sector and global health buyers. The company is led by Co-Founder/CEO Koenraad Wiedhaup and CSO Clarissa Koch, with Founder Jaap Goudsmit and Founder/CBO Ronald Brus, Executive Chairman Dinko Valerio, and CMO Jintanat Ananworanich providing senior leadership; Ben Verwaayen joined the Supervisory Board in June 2026.

Leyden Labs firmographics

Firmographics
Name
Leyden Labs
Legal name
Leyden Laboratories B.V.
Website
https://leydenlabs.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Leyden Labs is a Dutch clinical-stage biotech founded in 2020 developing intranasal antibody nasal sprays, led by PanFlu, which deliver broadly neutralizing antibodies to the respiratory mucosa for immediate protection against influenza and other respiratory viruses, serving governments and global health buyers for pandemic preparedness.
Ownership category
akta.pro rank

Leyden Labs industry classification

Industry
Product category
Infectious Disease Prophylactics
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Intranasal antibody therapy
  • Respiratory virus prophylaxis
  • Pandemic preparedness solutions
  • Broadly neutralizing antibodies
  • Mucosal protection platform

Where Leyden Labs is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Leyden Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Leyden Labs is developing and advancing toward commercialization of its intranasal antibody nasal spray products (PanFlu) for influenza and other respiratory virus prevention. The company aims to bring these products to market as prophylactic treatments for healthcare providers, governments, and potentially consumers for pandemic preparedness.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Leyden Labs product offering

Product offering

Core offering

Leyden Labs develops intranasal antibody-based nasal sprays that deliver broadly neutralizing antibodies directly to the respiratory mucosa to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. The company's lead candidate, PanFlu, uses the CR9114 antibody and is advancing through clinical trials toward regulatory approval and commercialization for pandemic preparedness and public health use.

Product overview

Leyden Labs is developing a portfolio of intranasal antibody-based products targeting respiratory viruses. The company's lead product is PanFlu, an antibody-based nasal spray using the broadly neutralizing CR9114 antibody. This is enabled by the company's Mucosal Protection Platform technology, which delivers protective antibodies directly to the nasal mucosa. The products aim to provide immediate, broad-spectrum protection against influenza, coronaviruses, and other respiratory viruses at the point of viral entry.

Differentiator

Problem solved

Functional benefit

Brands

  • PanFlu: Intranasal spray candidate delivering broadly neutralizing CR9114 antibody for protection against influenza and other respiratory viruses at the point of viral entry.
  • Mucosal Protection Platform

Products and services

  • PanFlu An antibody-based intranasal nasal spray for influenza prevention that delivers the broadly neutralizing CR9114 antibody directly to the respiratory mucosa. Phase 1 clinical studies demonstrated safety, tolerability, and protective antibody concentrations in 143 healthy volunteers, with non-human primate studies confirming protection against H1N1 infection and reduced viral load. Targeted at healthcare providers, governments, and global public health programs for pandemic preparedness.
  • Mucosal Protection Platform A technology platform that delivers broadly protective antibodies directly to the respiratory mucosa (nose and throat) to provide immediate protection against respiratory viruses including influenza and coronaviruses. Underpins Leyden Labs' intranasal product pipeline, including the lead candidate PanFlu.

Quantifiable outcome

  • Phase 1 studies (n=143 healthy volunteers) demonstrated that intranasal delivery of CR9114 antibody was safe, well-tolerated, and achieved protective concentrations in nasal mucosa
  • +2 more outcomes

Companies that use Leyden Labs

Customer profile

Segments2 records

Ideal customer profiles2 records

Leyden Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Leyden Labs partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Ben Verwaayen (Supervisory Board Member)minorOthers · 26 June 2026Appointed to the Supervisory Board, bringing international leadership experience from senior executive roles at global technology companies. Nominated by EIC Fund and Invest-NL.
  • CoV Biotechnology (Covbio)coreStrategic or Co-development Partner · 9 January 2025Acquired CoV Biotechnology to strengthen Leyden Labs' pandemic preparedness efforts in Asia. The acquisition expands the company's capabilities and geographic footprint in Asian markets for respiratory virus protection.
  • HERA (European Health Emergency Preparedness and Response Authority)coreStrategic or Co-development Partner · 1 January 2025Facilitated the €20 million EIB investment to advance Leyden Labs' intranasal antibody approach for pandemic preparedness in Europe. Represents a strategic alignment with European public health preparedness priorities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Leyden Labs competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Moderna is a leading mRNA vaccine and therapeutics company developing respiratory virus vaccines including mRNA-1010 and mRNA-1083 (flu+COVID combinations). It competes with Leyden Labs for the same pandemic preparedness and seasonal flu prophylaxis market, but with a fundamentally different technology platform (mRNA vs intranasal antibodies).
  • BioNTech: BioNTech is a leading mRNA therapeutics company with COVID and influenza vaccine programs and a broad oncology and infectious disease pipeline. It is comparable to Leyden Labs as a competing modality addressing the same pandemic preparedness and respiratory virus prophylaxis use cases.
  • Regeneron Pharmaceuticals: Regeneron is a leading monoclonal antibody company whose REGN-COV2 (casirivimab/imdevimab) demonstrated the feasibility of antibody-based prophylaxis for respiratory viruses. As a large biotech with established mAb manufacturing, it represents both a potential competitor and likely strategic acquirer of intranasal antibody programs like Leyden's.
  • AstraZeneca: AstraZeneca developed Evusheld (tixagevimab/cilgavimab), the leading antibody prophylaxis for COVID-19 in immunocompromised patients. It is comparable to Leyden Labs as a competing prophylactic mAb franchise targeting pandemic preparedness stockpiling budgets.
  • CSL Seqirus: CSL Seqirus is one of the world's largest influenza vaccine manufacturers and a major pandemic preparedness partner to governments. It is comparable to Leyden Labs as the incumbent channel and likely competitor/distributor for intranasal antibody products in government stockpiling markets.

Direct peers

  • Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing antibody-based therapeutics for serious infectious diseases including influenza (sotrovimab, VIR-2482) and COVID-19. It is the closest direct peer to Leyden Labs, pursuing prophylactic monoclonal antibodies against respiratory viruses through a different delivery route (intramuscular vs intranasal).
  • Arcturus Therapeutics: Arcturus is a clinical-stage mRNA and lipid nanoparticle company developing self-amplifying mRNA vaccines including a pandemic influenza vaccine (ARCT-2138). It is comparable to Leyden Labs as a competing modality addressing the same broad-protection influenza use case.
  • CureVac: CureVac is a clinical-stage mRNA company developing vaccines for infectious diseases including seasonal and pandemic influenza (CVSQIV). It competes with Leyden Labs for the same broad-protection respiratory virus market with an alternative technology platform.
  • Invivyd (formerly Adagio Therapeutics): Invivyd is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for COVID-19 and other viral diseases, with a focus on durable monoclonal antibodies for prophylaxis. It is directly comparable to Leyden Labs as a competing mAb-focused pandemic preparedness company.

Emerging players

  • Hummingbird Bioscience: Hummingbird Bioscience is a clinical-stage biotechnology company developing precision-engineered antibody therapeutics for oncology and infectious diseases. It is comparable to Leyden Labs as a fellow emerging antibody platform company, though focused on different therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Leyden Labs social profiles

Digital presence

Leyden Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leyden Labs leadership team

Management profile

Number of profiles

Profiles7 records

Leyden Labs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Leyden Labs funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leyden Labs M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leyden Labs

What does Leyden Labs do?

Leyden Labs develops intranasal antibody-based nasal sprays that deliver broadly neutralizing antibodies directly to the respiratory mucosa to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. The company's lead candidate, PanFlu, uses the CR9114 antibody and is advancing through clinical trials toward regulatory approval and commercialization for pandemic preparedness and public health use.

Is Leyden Labs a public or private company?

Leyden Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Leyden Labs founded?

Leyden Labs was founded in 2020. It employs 51 to 100 people.

Where is Leyden Labs based?

Leyden Labs is headquartered in Leiden, Netherlands, in the Europe region.

How does Leyden Labs make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Leyden Labs's main competitors?

Broad incumbents on record are Moderna, BioNTech, Regeneron Pharmaceuticals, AstraZeneca and CSL Seqirus. Direct peers are Vir Biotechnology, Arcturus Therapeutics, CureVac and Invivyd (formerly Adagio Therapeutics). Hummingbird Bioscience is listed as an emerging player.

Does Leyden Labs have an API?

No public API is recorded for Leyden Labs.

What industry is Leyden Labs in?

Leyden Labs's product category is Infectious Disease Prophylactics. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageLeyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma PatientsLeyden Labs reported positive Phase 1 results for RIG-101, an intranasal innate immune modulator, showing safety and expected antiviral response in healthy volunteers and asthma patients. The company plans to advance RIG-101 into Phase 2, with a human rhinovirus challenge study in asthma patients next.BioSpaceLeyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma PatientsLeyden Labs reported positive Phase 1 results for RIG-101, an intranasal innate immune modulator, showing safety and expected antiviral response in healthy volunteers and asthma patients. The company plans to advance RIG-101 into Phase 2, with a human rhinovirus challenge study in asthma patients next.MorningstarLeyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma PatientsLeyden Labs announced positive Phase 1 results for RIG-101, an intranasal innate immune modulator, showing safety and expected antiviral response in healthy volunteers and asthma patients. The company plans to advance RIG-101 into Phase 2, with a human rhinovirus challenge study in asthma patients next.European BiotechnologyLeyden Labs reveals RIGImmune acquisition with Phase 1 dataLeyden Labs reported positive Phase 1 results for intranasal RIG-101 and disclosed its acquisition of RIGImmune earlier in 2026. The drug was safe and well-tolerated, inducing interferons in asthma patients. The next trial will challenge patients with rhinovirus, with completion expected in February 2027.Tech.euThe Netherlands' top-funded tech companies in H1 2026Dutch tech companies raised about €1.9 billion in H1 2026, with the three largest rounds accounting for 44% of total funding. Semiconductors led with €570.5 million, followed by travel at €292.5 million, while healthtech had the most deals. Later-stage rounds dominated, with smaller earlier-stage investments.StartupriseTop Funding Wrap Of The Week – 22 June – 26 June 2026Multiple European startups collectively raised capital during the week of June 22–26, 2026, according to a funding roundup. The largest raise came from health insurance startup Alan, which secured €480 million at a €5.5 billion valuation, while biotech firms Bionyra Pharma (€143M) and Leyden Labs (€40M) also attracted significant investment alongside AI, deeptech, sports media, and fintech companies.Pulse 2.0Leyden Labs Raises €40 Million To Advance Respiratory Virus Protection PlatformLeyden Labs, a Dutch biotech company developing broadly protective nasal sprays for respiratory viruses, announced a €40 million financing round with participation from the European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio. The funding will advance the company's Mucosal Protection Platform through clinical development and support global access, particularly in low- and middle-income countries. The company also appointed Ben Verwaayen to its Supervisory Board, bringing international leadership experience from senior executive roles at global technology companies.Analytics InsightTop News Today: OpenAI’s AI Chip, Leyden Labs Funding, and MoreOpenAI has introduced its first in-house AI inference chip named Jalapeño, developed with Broadcom to enhance AI response speed and reduce power consumption. Leyden Labs secured €40 million in funding to advance its flu-blocking nasal spray through clinical trials, aiming to expand access, especially in lower-income countries. The article also discusses the potential for Bitcoin to remain weak before a recovery and the growing focus on screen-free technology by tech companies.BioWorldFinancings for June 26, 2026BioWorld published a financings brief for June 26, 2026, listing biopharma and med-tech companies raising money in public or private financings. The companies named include Grail, Hatch, Helus, Leyden, Lycia, Mesoblast, Optimeos, Pulsenmore, and Taysha.StartupriseBiotech Startup Leyden Labs €40 Mn in RoundDutch biotech startup Leyden Labs has raised €40 million in a funding round led by the European Innovation Council Fund, Invest-NL, the Gates Foundation Strategic Investment Fund, and ClavystBio. The investment will support the company's development of a nasal spray platform designed to deliver protective antibodies directly to the nose and throat to combat influenza and other respiratory viruses. Leyden Labs was also selected for the EIC STEP Scale Up programme and plans to advance its programs through clinical development toward global access.